Pharma Manufacturing Business Raising Funds In Mumbai

About Business

The business operates as a pharmaceutical contract development and manufacturing organization (CDMO) focused on formulation development and commercial manufacturing. Its activities include the production of liquid oral formulations, dermatological products, and sterile ophthalmic preparations for pharmaceutical companies.

Manufacturing Capabilities
The company has a manufacturing facility designed for sterile production and operates in compliance with internationally recognized regulatory standards, including EU-GMP guidelines. The facility supports the manufacturing of sterile semisolid products such as ointments, gels, and pre-filled syringes, along with non-sterile formulations including dermatological creams and liquid oral products.

Product Segments
The product portfolio covers several pharmaceutical categories:

Sterile / Ophthalmic Products
Eye care formulations including antibiotic, antiviral, anti-inflammatory, and lubricating ophthalmic ointments used for treating infections, inflammation, and dry eye conditions.

Dermatological Products
Topical treatments such as antifungal, antibacterial, corticosteroid, burn care, and anti-scabies creams used for managing skin infections, dermatitis, inflammation, and related conditions.

Liquid Oral Products
Oral syrups and liquid formulations including cough remedies, nutritional supplements, and medications used for respiratory health, nutritional support, and fever or pain management.

Service Offering
The business provides integrated services covering formulation development, dossier preparation, regulatory documentation, and commercial-scale manufacturing. These services allow pharmaceutical clients to manage the entire product lifecycle through a single partner.

Industry Experience
The operations are supported by more than two decades of experience in manufacturing topical formulations, dermatological products, and liquid oral medicines, contributing to consistent production standards and technical expertise.

Client Base
The business works with pharmaceutical companies seeking manufacturing partners for product development and commercial production. Clients typically value reliable documentation, protection of intellectual property, timely supply, and consistent product quality.

Clientele type

The business supplies its products to distributors in India as well as international distributors across multiple markets, including Kenya, Ethiopia, Myanmar, Cambodia, Libya, Nigeria, Chile, Ghana, Sri Lanka, the Philippines, Bolivia, Botswana, Yemen, Azerbaijan, Malawi, Kazakhstan, Turkmenistan, Uzbekistan, Zambia, and Papua New Guinea.

Premises

OWNED

Premise Size: 35000 sq. ft.

Market Value (in INR): 20.00 Cr

They have 3 manufacturing units, all of which are based in Tarapur only. The facility has a built-up capacity designed to support revenues of around INR 200 crore and is capable of manufacturing approximately 9 crore units annually. The plant operates with five dedicated manufacturing lines.

Asking Price Includes

The promoters are open to offering up to 20% equity stake in the business to a potential investor.

Asking Price

INR 25.00 Cr

Minimum ticket size

INR 5.00 Cr

Reason

The business is seeking a strategic partner to support expansion into additional markets and to explore the establishment of new manufacturing facilities in Africa.

More Details

Workforce
The business employs a team of approximately 200 people, including around 80 white-collar staff involved in management, technical, and administrative roles, and about 120 blue-collar employees engaged in manufacturing and operational activities.

Ownership Structure
The company operates as a family-owned business, with ownership and control held within the family.

Business Strengths
Key strengths include expertise in specialized dosage forms, established product registrations in multiple international markets, and factory approvals that support exports to various countries.

Future Growth Potential
The business has opportunities to expand by entering additional ROW (Rest of the World) markets, developing new pharmaceutical products, and introducing selected formulations into the Indian market.